Neochem Bio Solutions Limited (NEOCHEM)
Latest quarterly results (H2 FY26)
NEOCHEM delivery percentage
NSE end-of-day data for
On Fri, 16 Oct 2026, 97.73% of the NEOCHEM shares traded on NSE were taken to delivery, against the stock's own 20-session average of 80.25%. That is higher than usual for this stock. Turnover was only ₹58 lakh, so a handful of trades can move this figure.
Delivery in the last 5 sessions: 91.0% · 53.9% · 100.0% · 94.3% · 97.7%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Neochem Bio Solutions Limited has submitted its compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter and half-year ended 30th September, 2026. The certificate was issued by the company's Registrar and Transfer Agent, MUFG Intime India Private Limited, dated 3rd October, 2026. It confirms that securities received for dematerialisation during the period were duly verified, accepted or rejected, and listed on the exchange. This is a standard quarterly regulatory compliance filing with no impact on business operations or financials.
- Compliance certificate submitted under Regulation 74(5) of SEBI Regulations, 2018
- Covers the quarter and half-year ended 30th September, 2026
- RTA confirmation issued by MUFG Intime India Private Limited dated 03-10-2026
- Filing submitted to the National Stock Exchange on 08th October, 2026
Neochem Bio Solutions has submitted its FY26 investor presentation following its NSE SME listing, which raised Rs 42.7 crore. The company operates a 22,000 MTPA manufacturing facility in Ahmedabad, reporting capacity utilization of 52.7% (11,589 MT production) in FY26, up from 41.8% in FY25. The presentation highlights a revenue milestone exceeding Rs 11,000 lakhs (Rs 110 crore) in FY26 alongside diversification into Home and Personal Care (HPC), which reached 14.21% of revenue by September 2025.
- Installed manufacturing capacity stands at 22,000 MTPA with FY26 utilization rising to 52.7% (11,589 MT production).
- Raised Rs 42.7 crore via public issue on NSE SME platform.
- Reported FY26 revenue surpassing Rs 11,000 lakhs (Rs 110 crore), after achieving over Rs 6,000 lakhs in FY24.
- Home & Personal Care contribution expanded from 2.18% in FY23 to 14.21% by September 2025.
- Maintains 350+ customized formulations, 50+ pan-India distributors, and presence across 12 countries.
Neochem Bio Solutions Limited concluded its 9th Annual General Meeting held on September 21, 2026. A total of 1,21,09,804 votes were polled across 13 participating shareholders, representing 70.7317% of total outstanding shares. Shareholders unanimously passed both ordinary resolutions with 100% votes in favor and zero votes against. The approved resolutions include the adoption of FY2026 audited standalone financial statements and the re-appointment of retiring director Mr. Dinesh Chopra.
- Total 1,21,09,804 votes polled, representing 70.7317% of the 1,71,20,753 outstanding shares
- 100% of votes cast were in favor of both ordinary resolutions with zero dissenting votes
- 528 total shareholders recorded as of the cut-off date of September 14, 2026
- Promoter group polled 1,14,18,575 votes out of 1,14,49,950 shares held (99.726% participation)
Neochem Bio Solutions Limited disclosed that Promoter and Managing Director Swapnil Ramesh Bhai Makati purchased 1,200 equity shares via open market on September 18, 2026. The total transaction value was ₹13,50,000. Following the acquisition, the promoter's shareholding marginally increased from 54.74% (93,72,875 shares) to 54.75% (93,74,075 shares).
- Promoter Swapnil Ramesh Bhai Makati acquired 1,200 equity shares on September 18, 2026
- Total value of the transaction stands at ₹13,50,000 via on-market purchase
- Shareholding increased marginally from 54.74% to 54.75%
- Total post-acquisition holding stands at 93,74,075 equity shares
Neochem Bio Solutions Limited has disclosed an insider trading transaction under SEBI (PIT) Regulations. Promoter Swapnil Rameshbhai Makati acquired 7,200 equity shares via an on-market purchase on September 9, 2026, for a total value of Rs 7,44,600. Following this transaction, his stake marginally increased from 54.70% (93,65,675 shares) to 54.74% (93,72,875 shares).
- Acquisition of 7,200 equity shares (0.042% stake) via an on-market trade
- Total transaction consideration of Rs 7,44,600
- Promoter shareholding increased from 54.70% to 54.74%
- Trade executed on September 9, 2026, and reported on September 10, 2026
Neochem Bio Solutions Limited has appointed Mr. Siddharth Raj as Business Head – (Textiles) Corporate Accounts, designated as Senior Management Personnel, effective August 29, 2026. Mr. Raj brings over 20 years of experience in the textile dyes and chemicals sector, including over 15 years at Huntsman International and senior roles at Archroma International. He holds a B.Tech. in Textile Chemistry (2006 batch) from TIT&S, Bhiwani, and will report to the Managing Director. The appointment is aimed at driving commercial growth in Neochem's textile corporate accounts vertical.
- Appointed Mr. Siddharth Raj as Business Head – (Textiles) Corporate Accounts effective August 29, 2026
- Appointee brings over 20 years of experience in textile dyes and chemicals
- Prior experience includes over 15 years at Huntsman International and leadership roles at Archroma International
- Holds a B.Tech. in Textile Chemistry from TIT&S, Bhiwani (2006 batch)
Neochem Bio Solutions Limited has dispatched letters containing the web-link to its FY 2025-26 Annual Report to shareholders whose email addresses are not registered with the company or depositories as of the cut-off date August 21, 2026. The company announced that its 9th Annual General Meeting (AGM) will be held on Monday, September 21, 2026, at 4:00 PM IST via Video Conferencing. Additionally, the filing serves as a reminder to physical security holders to complete mandatory KYC updates and dematerialization in compliance with SEBI circulars.
- 9th Annual General Meeting scheduled for Monday, September 21, 2026, at 4:00 PM IST via Video Conferencing
- Cut-off date for dispatch of annual report web-link notice was August 21, 2026
- Annual Report for FY 2025-26 made accessible on company website pursuant to Regulation 36(1)(b) of SEBI LODR
- Reminder issued regarding mandatory KYC updates under SEBI circular dated May 7, 2024
Neochem Bio Solutions has issued the notice for its 9th Annual General Meeting (AGM) scheduled for September 21, 2026, alongside publishing its FY 2025-26 Annual Report. For FY26, the company reported a 32% increase in revenue from operations to ₹110.7 crore and a 62% surge in Net Profit to ₹12 crore. Following its IPO during the year, the company strengthened its balance sheet, cutting its debt-to-equity ratio from 1.80x to 0.23x. Total annual manufacturing capacity stands at 22,000 MTP.
- 9th AGM scheduled to be held on Monday, September 21, 2026 at 4:00 PM IST via Video Conferencing.
- FY26 revenue from operations increased 32% YoY to ₹110.7 crore, with EBITDA up 53% to ₹22.6 crore.
- FY26 PAT grew 62% YoY to ₹12 crore, with PAT margin reaching 10.6%.
- Debt-to-equity ratio reduced sharply from 1.80x in FY25 to 0.23x in FY26 post-IPO debt repayment.
Neochem Bio Solutions Limited has announced the outcome of its Board of Directors meeting held on August 24, 2026. The Board approved the Notice for convening the 9th Annual General Meeting (AGM) along with the Directors' Report for the financial year ended March 31, 2026. The AGM has been scheduled for Monday, September 21, 2026, at 4:00 PM IST via Video Conferencing / Other Audio Visual Means. The full Annual Report for FY 2025-26 will be dispatched and uploaded to the exchange in due course.
- 9th Annual General Meeting scheduled for Monday, September 21, 2026, at 4:00 PM IST
- Board approved the Directors' Report and notice for the financial year ended March 31, 2026
- Meeting conducted via Video Conferencing / Other Audio Visual Means
- Board meeting commenced at 04:00 PM IST and concluded at 05:55 PM IST on August 24, 2026
Neochem Bio Solutions Limited has informed the exchange regarding the resignation of Mr. Hitesh Wadher, Vice President - Marketing, who is designated as Senior Management Personnel (SMP). The resignation was tendered on August 21, 2026, to pursue other career opportunities. He will be relieved from his duties effective August 31, 2026. The company confirmed there are no other material reasons for the departure.
- Resignation of Mr. Hitesh Wadher, Vice President - Marketing (Senior Management Personnel)
- Resignation letter tendered on August 21, 2026
- Cessation effective from August 31, 2026
- Reason stated is to pursue better career opportunities with no other material reasons
Neochem Bio Solutions Limited has filed its Structured Digital Database (SDD) compliance certificate for the quarter ended June 30, 2026. This is a mandatory filing under Regulations 3(5) and 3(6) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The certificate confirms that the company maintains a digital record of individuals with whom unpublished price-sensitive information (UPSI) is shared. This is a routine administrative procedure for listed companies and does not impact financial performance.
- Compliance certificate submitted for the quarter ended June 30, 2026
- Adherence to Regulation 3(5) and 3(6) of SEBI (PIT) Regulations, 2015
- Document submitted to the National Stock Exchange on July 30, 2026
Swapnil R. Makati, the Managing Director and Promoter of Neochem Bio Solutions Limited, purchased 6,000 equity shares of the company on July 28, 2026. The transaction was valued at ₹5,44,560 and executed through an open market purchase on the NSE. This acquisition marginally increases the promoter's stake from 54.67% to 54.70%. While the volume is small, insider buying is typically viewed as a signal of management's confidence in the company's valuation.
- Purchase of 6,000 equity shares by Managing Director Swapnil R. Makati
- Total transaction value of ₹5,44,560 executed on July 28, 2026
- Promoter holding increased from 54.67% to 54.70% (a 0.03% increase)
- Transaction conducted via open market purchase on the National Stock Exchange
Managing Director Swapnil R. Makati acquired 7,200 equity shares of Neochem Bio Solutions Limited on July 27, 2026, through an open market transaction. The total purchase value amounted to Rs 6,43,020, reflecting an implied price of approximately Rs 89.31 per share. This transaction marginally increased the promoter's stake from 54.63% to 54.67%. While the volume is small, open-market purchases by top management are generally perceived as a positive signal of confidence in the company's valuation.
- Purchase of 7,200 equity shares by Managing Director Swapnil R. Makati
- Total transaction value of Rs 6,43,020 executed on the NSE
- Promoter stake increased by 0.042% to a total of 54.67%
- Transaction completed on July 27, 2026, via open market purchase
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Products & Services
Bio-based chemical solutions and technologies as indicated by the company name Neochem Bio Solutions Limited; specific product categories are not disclosed in available documents.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Geographic Concentration Risk
The company is headquartered in Ahmedabad, Gujarat, but specific revenue concentration by region is not disclosed.
